@article {ZengF506, author = {Linan Zeng and Jinhui Tian and Fujian Song and Wenrui Li and Lucan Jiang and Ge Gui and Yang Zhang and Long Ge and Jing Shi and Xin Sun and Dezhi Mu and Lingli Zhang}, title = {Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis}, volume = {103}, number = {6}, pages = {F506--F511}, year = {2018}, doi = {10.1136/archdischild-2017-313759}, publisher = {BMJ Publishing Group}, abstract = {Objective To determine the comparative efficacy and safety of corticosteroids in the prevention of bronchopulmonary dysplasia (BPD) in preterm infants.Study design We systematically searched PubMed, EMBASE and the Cochrane Library. Two reviewers independently selected randomised controlled trials (RCTs) of postnatal corticosteroids in preterm infants. A Bayesian network meta-analysis and subgroup analyses were performed.Results We included 47 RCTs with 6747 participants. The use of dexamethasone at either high dose or low dose decreased the risk of BPD (OR 0.29, 95\% credible interval (CrI) 0.14 to 0.52; OR 0.58, 95\% CrI 0.39 to 0.76, respectively). High-dose dexamethasone was more effective than hydrocortisone, beclomethasone and low-dose dexamethasone. Early and long-term dexamethasone at either high dose or low dose decreased the risk of BPD (OR 0.11, 95\% CrI 0.02 to 0.4; OR 0.37, 95\% CrI 0.16 to 0.67, respectively). There were no statistically significant differences in the risk of cerebral palsy (CP) between different corticosteroids. However, high-dose and long-term dexamethasone ranked lower than placebo and other regimens in terms of CP. Subgroup analyses indicated budesonide was associated with a decreased risk of BPD in extremely preterm and extremely low birthweight infants (OR 0.60, 95\% CrI 0.36 to 0.93).Conclusions Dexamethasone can reduce the risk of BPD in preterm infants. Of the different dexamethasone regimens, aggressive initiation seems beneficial, while a combination of high-dose and long-term use should be avoided because of the possible adverse neurodevelopmental outcome. Dexamethasone and inhaled corticosteroids need to be further evaluated in large-scale RCTs with long-term follow-ups.}, issn = {1359-2998}, URL = {https://fn.bmj.com/content/103/6/F506}, eprint = {https://fn.bmj.com/content/103/6/F506.full.pdf}, journal = {Archives of Disease in Childhood - Fetal and Neonatal Edition} }